glp-1 moa and the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 Receptor Agonists as Treatments

As only one patient with IIH-WOP was treated with a GLP-1-RA, this was insufficient to conduct subgroup analyses, so we could only perform sensitivity analyses removing IIH-WOP patients to exclude potential confounding effect on our results

So there is no time-bound answer to this question, as it depends on the individuals care plan with their prescribing provider

Any dietary changes should be implemented as part of a comprehensive management plan that includes regular monitoring of glycaemic control, weight, and treatment response

Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment

Glucagon-Like Peptide 1 Receptor Agonists and Coronary Events Composite Outcomes Including Coronary Events Coronary events form a part of cardiovascular composite outcomes, such as cardiovascular mortality and major adverse cardiovascular events (MACE)